Cargando…

Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study

OBJECTIVE: To estimate benefits and harms of different colorectal cancer screening strategies, stratified by (baseline) 15-year colorectal cancer risk. DESIGN: Microsimulation modelling study using MIcrosimulation SCreening ANalysis-Colon (MISCAN-Colon). SETTING: A parallel guideline committee (BMJ...

Descripción completa

Detalles Bibliográficos
Autores principales: Buskermolen, Maaike, Cenin, Dayna R, Helsingen, Lise M, Guyatt, Gordon, Vandvik, Per Olav, Haug, Ulrike, Bretthauer, Michael, Lansdorp-Vogelaar, Iris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6774435/
https://www.ncbi.nlm.nih.gov/pubmed/31578177
http://dx.doi.org/10.1136/bmj.l5383
_version_ 1783456079641837568
author Buskermolen, Maaike
Cenin, Dayna R
Helsingen, Lise M
Guyatt, Gordon
Vandvik, Per Olav
Haug, Ulrike
Bretthauer, Michael
Lansdorp-Vogelaar, Iris
author_facet Buskermolen, Maaike
Cenin, Dayna R
Helsingen, Lise M
Guyatt, Gordon
Vandvik, Per Olav
Haug, Ulrike
Bretthauer, Michael
Lansdorp-Vogelaar, Iris
author_sort Buskermolen, Maaike
collection PubMed
description OBJECTIVE: To estimate benefits and harms of different colorectal cancer screening strategies, stratified by (baseline) 15-year colorectal cancer risk. DESIGN: Microsimulation modelling study using MIcrosimulation SCreening ANalysis-Colon (MISCAN-Colon). SETTING: A parallel guideline committee (BMJ Rapid Recommendations) defined the time frame and screening interventions, including selection of outcome measures. POPULATION: Norwegian men and women aged 50-79 years with varying 15-year colorectal cancer risk (1-7%). COMPARISONS: Four screening strategies were compared with no screening: biennial or annual faecal immunochemical test (FIT) or single sigmoidoscopy or colonoscopy at 100% adherence. MAIN OUTCOME MEASURES: Colorectal cancer mortality and incidence, burdens, and harms over 15 years of follow-up. The certainty of the evidence was assessed using the GRADE approach. RESULTS: Over 15 years of follow-up, screening individuals aged 50-79 at 3% risk of colorectal cancer with annual FIT or single colonoscopy reduced colorectal cancer mortality by 6 per 1000 individuals. Single sigmoidoscopy and biennial FIT reduced it by 5 per 1000 individuals. Colonoscopy, sigmoidoscopy, and annual FIT reduced colorectal cancer incidence by 10, 8, and 4 per 1000 individuals, respectively. The estimated incidence reduction for biennial FIT was 1 per 1000 individuals. Serious harms were estimated to be between 3 per 1000 (biennial FIT) and 5 per 1000 individuals (colonoscopy); harms increased with older age. The absolute benefits of screening increased with increasing colorectal cancer risk, while harms were less affected by baseline risk. Results were sensitive to the setting defined by the guideline panel. Because of uncertainty associated with modelling assumptions, we applied a GRADE rating of low certainty evidence to all estimates. CONCLUSIONS: Over a 15 year period, all screening strategies may reduce colorectal cancer mortality to a similar extent. Colonoscopy and sigmoidoscopy may also reduce colorectal cancer incidence, while FIT shows a smaller incidence reduction. Harms are rare and of similar magnitude for all screening strategies.
format Online
Article
Text
id pubmed-6774435
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group Ltd.
record_format MEDLINE/PubMed
spelling pubmed-67744352019-10-21 Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study Buskermolen, Maaike Cenin, Dayna R Helsingen, Lise M Guyatt, Gordon Vandvik, Per Olav Haug, Ulrike Bretthauer, Michael Lansdorp-Vogelaar, Iris BMJ Research OBJECTIVE: To estimate benefits and harms of different colorectal cancer screening strategies, stratified by (baseline) 15-year colorectal cancer risk. DESIGN: Microsimulation modelling study using MIcrosimulation SCreening ANalysis-Colon (MISCAN-Colon). SETTING: A parallel guideline committee (BMJ Rapid Recommendations) defined the time frame and screening interventions, including selection of outcome measures. POPULATION: Norwegian men and women aged 50-79 years with varying 15-year colorectal cancer risk (1-7%). COMPARISONS: Four screening strategies were compared with no screening: biennial or annual faecal immunochemical test (FIT) or single sigmoidoscopy or colonoscopy at 100% adherence. MAIN OUTCOME MEASURES: Colorectal cancer mortality and incidence, burdens, and harms over 15 years of follow-up. The certainty of the evidence was assessed using the GRADE approach. RESULTS: Over 15 years of follow-up, screening individuals aged 50-79 at 3% risk of colorectal cancer with annual FIT or single colonoscopy reduced colorectal cancer mortality by 6 per 1000 individuals. Single sigmoidoscopy and biennial FIT reduced it by 5 per 1000 individuals. Colonoscopy, sigmoidoscopy, and annual FIT reduced colorectal cancer incidence by 10, 8, and 4 per 1000 individuals, respectively. The estimated incidence reduction for biennial FIT was 1 per 1000 individuals. Serious harms were estimated to be between 3 per 1000 (biennial FIT) and 5 per 1000 individuals (colonoscopy); harms increased with older age. The absolute benefits of screening increased with increasing colorectal cancer risk, while harms were less affected by baseline risk. Results were sensitive to the setting defined by the guideline panel. Because of uncertainty associated with modelling assumptions, we applied a GRADE rating of low certainty evidence to all estimates. CONCLUSIONS: Over a 15 year period, all screening strategies may reduce colorectal cancer mortality to a similar extent. Colonoscopy and sigmoidoscopy may also reduce colorectal cancer incidence, while FIT shows a smaller incidence reduction. Harms are rare and of similar magnitude for all screening strategies. BMJ Publishing Group Ltd. 2019-10-02 /pmc/articles/PMC6774435/ /pubmed/31578177 http://dx.doi.org/10.1136/bmj.l5383 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Research
Buskermolen, Maaike
Cenin, Dayna R
Helsingen, Lise M
Guyatt, Gordon
Vandvik, Per Olav
Haug, Ulrike
Bretthauer, Michael
Lansdorp-Vogelaar, Iris
Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study
title Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study
title_full Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study
title_fullStr Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study
title_full_unstemmed Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study
title_short Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study
title_sort colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6774435/
https://www.ncbi.nlm.nih.gov/pubmed/31578177
http://dx.doi.org/10.1136/bmj.l5383
work_keys_str_mv AT buskermolenmaaike colorectalcancerscreeningwithfaecalimmunochemicaltestingsigmoidoscopyorcolonoscopyamicrosimulationmodellingstudy
AT cenindaynar colorectalcancerscreeningwithfaecalimmunochemicaltestingsigmoidoscopyorcolonoscopyamicrosimulationmodellingstudy
AT helsingenlisem colorectalcancerscreeningwithfaecalimmunochemicaltestingsigmoidoscopyorcolonoscopyamicrosimulationmodellingstudy
AT guyattgordon colorectalcancerscreeningwithfaecalimmunochemicaltestingsigmoidoscopyorcolonoscopyamicrosimulationmodellingstudy
AT vandvikperolav colorectalcancerscreeningwithfaecalimmunochemicaltestingsigmoidoscopyorcolonoscopyamicrosimulationmodellingstudy
AT haugulrike colorectalcancerscreeningwithfaecalimmunochemicaltestingsigmoidoscopyorcolonoscopyamicrosimulationmodellingstudy
AT bretthauermichael colorectalcancerscreeningwithfaecalimmunochemicaltestingsigmoidoscopyorcolonoscopyamicrosimulationmodellingstudy
AT lansdorpvogelaariris colorectalcancerscreeningwithfaecalimmunochemicaltestingsigmoidoscopyorcolonoscopyamicrosimulationmodellingstudy